These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 18060046)
1. Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/p53 pathway lesions but not p16 Ink4a loss. Debies MT; Gestl SA; Mathers JL; Mikse OR; Leonard TL; Moody SE; Chodosh LA; Cardiff RD; Gunther EJ J Clin Invest; 2008 Jan; 118(1):51-63. PubMed ID: 18060046 [TBL] [Abstract][Full Text] [Related]
2. Ink4a/Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse. Khoo CM; Carrasco DR; Bosenberg MW; Paik JH; Depinho RA Proc Natl Acad Sci U S A; 2007 Mar; 104(10):3931-6. PubMed ID: 17360455 [TBL] [Abstract][Full Text] [Related]
3. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis. Sharpless NE; Ramsey MR; Balasubramanian P; Castrillon DH; DePinho RA Oncogene; 2004 Jan; 23(2):379-85. PubMed ID: 14724566 [TBL] [Abstract][Full Text] [Related]
4. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Bardeesy N; Aguirre AJ; Chu GC; Cheng KH; Lopez LV; Hezel AF; Feng B; Brennan C; Weissleder R; Mahmood U; Hanahan D; Redston MS; Chin L; Depinho RA Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5947-52. PubMed ID: 16585505 [TBL] [Abstract][Full Text] [Related]
5. Resistance of primary cultured mouse hepatic tumor cells to cellular senescence despite expression of p16(Ink4a), p19(Arf), p53, and p21(Waf1/Cip1). Obata M; Imamura E; Yoshida Y; Goto J; Kishibe K; Yasuda A; Ogawa K Mol Carcinog; 2001 Sep; 32(1):9-18. PubMed ID: 11568971 [TBL] [Abstract][Full Text] [Related]
6. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Gunther EJ; Moody SE; Belka GK; Hahn KT; Innocent N; Dugan KD; Cardiff RD; Chodosh LA Genes Dev; 2003 Feb; 17(4):488-501. PubMed ID: 12600942 [TBL] [Abstract][Full Text] [Related]
7. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis. D'Amico M; Wu K; Di Vizio D; Reutens AT; Stahl M; Fu M; Albanese C; Russell RG; Muller WJ; White M; Negassa A; Lee HW; DePinho RA; Pestell RG Cancer Res; 2003 Jun; 63(12):3395-402. PubMed ID: 12810676 [TBL] [Abstract][Full Text] [Related]
8. The inhibitor of cyclin-dependent kinase 4a/alternative reading frame (INK4a/ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct cis elements. D'Amico M; Wu K; Fu M; Rao M; Albanese C; Russell RG; Lian H; Bregman D; White MA; Pestell RG Cancer Res; 2004 Jun; 64(12):4122-30. PubMed ID: 15205322 [TBL] [Abstract][Full Text] [Related]
9. Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia. Bardeesy N; Morgan J; Sinha M; Signoretti S; Srivastava S; Loda M; Merlino G; DePinho RA Mol Cell Biol; 2002 Jan; 22(2):635-43. PubMed ID: 11756558 [TBL] [Abstract][Full Text] [Related]
10. Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Bardeesy N; Bastian BC; Hezel A; Pinkel D; DePinho RA; Chin L Mol Cell Biol; 2001 Mar; 21(6):2144-53. PubMed ID: 11238948 [TBL] [Abstract][Full Text] [Related]
11. p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways. Kelly-Spratt KS; Gurley KE; Yasui Y; Kemp CJ PLoS Biol; 2004 Aug; 2(8):E242. PubMed ID: 15314658 [TBL] [Abstract][Full Text] [Related]
12. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Bulavin DV; Phillips C; Nannenga B; Timofeev O; Donehower LA; Anderson CW; Appella E; Fornace AJ Nat Genet; 2004 Apr; 36(4):343-50. PubMed ID: 14991053 [TBL] [Abstract][Full Text] [Related]
13. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma. Edmunds SC; Kelsell DP; Hungerford JL; Cree IA Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501 [TBL] [Abstract][Full Text] [Related]
14. A p53/ARF-dependent anticancer barrier activates senescence and blocks tumorigenesis without impacting apoptosis. Sinha VC; Qin L; Li Y Mol Cancer Res; 2015 Feb; 13(2):231-8. PubMed ID: 25253740 [TBL] [Abstract][Full Text] [Related]
15. Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice. Wang Y; Zhang Z; Kastens E; Lubet RA; You M Cancer Res; 2003 Aug; 63(15):4389-95. PubMed ID: 12907609 [TBL] [Abstract][Full Text] [Related]
16. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Lin AW; Lowe SW Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5025-30. PubMed ID: 11309506 [TBL] [Abstract][Full Text] [Related]
17. Depletion of ERK2 but not ERK1 abrogates oncogenic Ras-induced senescence. Shin J; Yang J; Lee JC; Baek KH Cell Signal; 2013 Dec; 25(12):2540-7. PubMed ID: 23993963 [TBL] [Abstract][Full Text] [Related]
18. p53 and p16 Azzopardi S; Pang S; Klimstra DS; Du YN Neoplasia; 2016 Oct; 18(10):610-617. PubMed ID: 27664376 [TBL] [Abstract][Full Text] [Related]
19. Definition of three minimal deleted regions by comprehensive allelotyping and mutational screening of FHIT,p16(INK4A), and p19(ARF) genes in nasopharyngeal carcinoma. Ko JY; Lee TC; Hsiao CF; Lin GL; Yen SH; Chen KY; Hsiung CA; Chen PJ; Hsu MM; Jou YS Cancer; 2002 Apr; 94(7):1987-96. PubMed ID: 11932901 [TBL] [Abstract][Full Text] [Related]
20. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis. Kanellou P; Zaravinos A; Zioga M; Stratigos A; Baritaki S; Soufla G; Zoras O; Spandidos DA Cancer Lett; 2008 Jun; 264(1):145-61. PubMed ID: 18331779 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]